Cardiac Guidance vs ElucidVivo A.3
AI Verdict
Choose Cardiac Guidance if…
Choose Cardiac Guidance if your primary goal is to democratize access to cardiac assessments by enabling healthcare professionals, including those without extensive ultrasound experience, to acquire diagnostic-quality cardiac ultrasound images at the point of care. This tool is ideal for settings focused on early disease detection and rapid, accessible cardiac evaluations, leveraging real-time AI guidance for image acquisition and automated quality assessment.
View Cardiac Guidance →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify patients with atherosclerosis and optimize treatment decisions. This system is best suited for specialists needing detailed visualization of plaque characteristics, including lipid-rich necrotic core and calcifications, validated against histology, to inform complex cardiovascular and vascular surgery interventions.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cardiac Guidance | ElucidVivo A.3 |
|---|---|---|
| Deployment | Caption Guidance is deployed in acute point-of-care settings, including emergency and anesthesiology departments and critical care units. It is also used in doctors' offices and can be used for at-home care. | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cardiac GuidanceCardiac Guidance (Tool A) is explicitly designed to empower non-expert ultrasound users with real-time AI guidance, turn-by-turn probe instructions, and automated quality assessment, significantly simplifying a complex procedure. This focus on making advanced imaging accessible to a broader range of healthcare professionals gives it a clear advantage in usability.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 (Tool B) offers a highly specialized and quantitative analysis of arterial plaque composition and stability from CT angiography, validated against ground-truth histology. Its ability to objectively quantify plaque components and derive FFRct provides deeper, more precise diagnostic and prognostic insights for atherosclerosis, directly optimizing treatment decisions.
Pricing & Value
Cardiac GuidanceBoth tools require contacting the vendor for pricing, limiting transparency. However, Cardiac Guidance (Tool A) explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for healthcare organizations and contribute significantly to its overall value and readiness for deployment in a regulated environment.
Enterprise Readiness
Cardiac GuidanceBoth tools are FDA-cleared and designed for integration within healthcare environments. Cardiac Guidance (Tool A) explicitly confirms HIPAA compliance and the provision of a BAA, which are fundamental requirements for enterprise deployment in healthcare and offer greater assurance regarding data security and regulatory adherence.
Innovation
ElucidVivo A.3While Cardiac Guidance (Tool A) innovates by democratizing cardiac ultrasound acquisition, ElucidVivo A.3 (Tool B) presents a more profound innovation in diagnostic precision. Its AI-powered, histologically validated quantitative analysis of arterial plaque composition and the derivation of FFRct offer novel and deeper insights into atherosclerosis, pushing the boundaries of non-invasive cardiovascular assessment.
Support & Docs
Cardiac GuidanceCardiac Guidance (Tool A) explicitly mentions the availability of an electronic Operator's Manual accessible both for instructions and within the Vscan Air app, indicating readily available user documentation. In contrast, the provided information for ElucidVivo A.3 (Tool B) does not detail specific support channels or documentation availability.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cardiac Guidance | ElucidVivo A.3 |
|---|---|---|
| Name | Cardiac Guidance | ElucidVivo A.3 |
| Company | Caption Health | Elucid Bioimaging |
| Primary Clinical Focus | Acquiring and interpreting diagnostic-quality cardiac ultrasound images at the point of care for early disease detection and accessible cardiac care. | Quantitative analysis of arterial plaque composition and stability from CT angiography for atherosclerosis patient stratification and optimized treatment decisions. |
| Input Imaging Modality | Cardiac ultrasound images | CT angiography |
| Key AI Functionality | Real-time AI guidance for cardiac ultrasound image acquisition, automated quality assessment, auto-capture of diagnostic-quality images, automated left ventricular ejection fraction (EF) calculation. | AI-powered quantitative analysis of arterial plaque, visualization of lesion-level plaque composition, 3D visualization of highlighted vessels, derivation of fractional flow reserve (FFRct). |
| Specific Measurements/Outputs | Automated left ventricular ejection fraction (EF) calculation, support for 10 standard echocardiographic views. | Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; derives fractional flow reserve (FFRct). |
| Intended User/Skill Level | Healthcare professionals, designed for use by non-expert ultrasound users. | Physicians (aids in atherosclerosis patient stratification and optimizes treatment decisions). |
Videos
Demos, reviews, and walkthroughs featuring Cardiac Guidance and ElucidVivo A.3.